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MTERFmily of proteins has four members, named MTERF1 to MTERF4, which were
identiﬁed in homology searches using the mitochondrial transcription termination factor, mTERF (here
denotedMTERF1) as query. MTERF1 andMTERF3 are known to participate in the control of mitochondrial DNA
transcription, but the function of the other two proteins is not known. We here investigate the structure and
function of MTERF2. Protein import experiments using isolated organelles conﬁrm that MTERF2 is a
mitochondrial protein. Edmandegradation ofMTERF2 isolated fromstably transfectedHeLa cells demonstrates
that matureMTERF2 lacks a targeting peptide (amino acids 1–35) present in the precursor form of the protein.
MTERF2 is a monomer in isolation and displays a non sequence-speciﬁc DNA-binding activity. In vivo
quantiﬁcation experiments demonstrate that MTERF2 is relatively abundant, with one monomer present per
∼265 bp of mtDNA. In comparison, the mtDNA packaging factor TFAM is present at a ratio of one molecule per
∼10–12 bp of mtDNA. Using formaldehyde cross-linking we demonstrate that MTERF2 is present in nucleoids,
and therefore must be located in close proximity to mtDNA. Taken together, our work provides a basic
biochemical characterization of MTERF2, paving the way for future functional studies.
© 2009 Elsevier B.V. All rights reserved.1. IntroductionThe mammalian mitochondrial DNA (mtDNA) is a circular double-
stranded molecule of ∼16 kb, which is organized in nucleoprotein
particles called nucleoids [1]. Themitochondrial genome encodes for a
small but essential number of genes necessary for the biological
function of the organelle. However, all the trans-active factors directly
involved in mtDNA replication, transcription, and translation are
speciﬁed by nuclear genes. Therefore, there must be a regulated
communication between the mitochondrial and nuclear genomes
[2,3]. Light strand (L-strand) transcription initiates from one single
promoter (Light Strand Promoter or LSP) located in a non-coding
region of mtDNA called the control region, while heavy strand (H-
strand) transcription is initiated from two different promoters (Heavy
Strand Promoter 1 and 2 or HSP1 and HSP2). HSP1 is also located in the
control region, whereas HSP2 is located at the 3′-end of the tRNAPhe
coding gene, ∼100 bp downstream of HSP1 [4]. Transcription of the
mtDNA from LSP and HSP2 promoters gives rise to two polycistronic
precursor RNA species, which encompass almost the entire length of
the mtDNA. The two transcripts are subsequently processed toistry andCell Biology, Göteborg
3826; fax: +46 31 416108.
. Gustafsson).
ll rights reserved.produce the individual mRNAs, rRNAs and tRNAs. Transcription
initiation at HSP1 starts directly upstream of the tRNAPhe gene and
spans the tRNAPhe, 12S rRNA, 16S rRNA, and tRNAVal genes [5].
The basic components of the mammalian mitochondrial transcrip-
tion machinery are the mitochondrial RNA polymerase (POLRMT), the
mitochondrial transcription factor A (TFAM), and the mitochondrial
transcription factor B1 or B2 (TFB1Mor TFB2M). In combination, these
factors can initiate transcription from mtDNA promoters in vitro [6].
TFAM is an abundant high-mobility-group-box proteinwith the ability
to bind and bend the mtDNA [7]. In addition to its role as a basal
transcription factor [8], TFAM also has a structural role as it
contributes to the packaging of mtDNA into nucleoids [9,10]. A speciﬁc
transcription termination event takes place downstream of the 16S
rRNA gene and is mediated by the mitochondrial transcription
termination factor MTERF1 (also known as mTERF), which binds a
28 bp region within the tRNALeu (UUR) gene [11,12]. MTERF1 has been
shown to terminate transcription in an in vitro transcription system
using puriﬁed recombinant proteins [13]. In addition, MTERF1 has
been reported to interact with a site in close proximity to the HSP1
promoter [14]. This simultaneous binding of the protein to its two
binding sites has been suggested to create a loop that facilitates
re-initiation of this transcription unit. Besides its role in mtDNA
transcription, MTERF1 has been reported to act as modulator of
mtDNA replication in human cells [15].
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coding for homologues to MTERF1 (denoted MTERF2, MTERF3, and
MTERF4), all of them with predicted mitochondrial localization [16].
MTERF3 is localized to the mitochondrial matrix where it interacts
with the mitochondrial promoter region and negatively regulates
transcription initiation [17]. Consequently, depletion of the MTERF3
protein in heart mitochondria of knock-out mice leads to a dramatic
increase in promoter proximal transcripts. MTERF3 does not appear to
terminate mitochondrial transcription, but rather regulates transcrip-
tion initiation events, although the exact mechanism remains to be
elucidated.
MTERF2 is another member of the MTERF family, which co-
localizes with mitochondria and has a high expression in heart, liver
and skeletal muscle [18]. Transcription of the MTERF2 gene was
decreased upon addition of serum in serum-starved cells, which led to
suggest that it is a novel serum-inhibitory factor, participating in the
regulation of mtDNA transcription. We here present a biochemical
characterization of the MTERF2 protein. Our analyses reveal that
MTERF2 is a mitochondrial protein, produced as a precursor form and
cleaved upon import to the organelle. MTERF2 binds DNA in a non
sequence-speciﬁc manner and using formaldehyde cross-linking we
demonstrate that MTERF2 is present in nucleoids and therefore
operates in close proximity to mtDNA.
2. Materials and methods
2.1. Mitochondrial protein import assay
The cDNA encoding the full-length human MTERF2 protein was
cloned into pBluescript II SK(+) (Stratagene). The recombinant
plasmid was used to express the MTERF2 protein in vitro using the
TNT® Coupled Reticulocyte Lysate System (Promega) according to the
manufacturer's instructions and in the presence of [35S]-methionine.
Mitochondria were freshly isolated from rat livers by differential
centrifugation and mitochondrial import assay was performed as
described in [17].
2.2. hMTERF2-FLAG protein puriﬁcation and Edman degradation
The cDNA encoding the full-length human MTERF2 protein with a
FLAG-tag at its C-terminus was cloned into pTRE-Tight (Clontech) to
obtain the pTRE-FLAG2 vector. HeLa TetOn cells (Clontech) were
stably co-transfected with pTRE-FLAG2 and a linear hygromycin
resistance marker following the manufacturer's instructions. Cells
were grown inmonolayer in D-MEMmedium supplemented with 10%
fetal calf serum, 1% streptomycin, 1% penicillin, and 200 μg/ml
hygromycin. The expression of hMTERF2-FLAGwas induced by adding
3 μg/ml doxycycline to the incubation medium, and cells were
harvested after 72 h of induction. Approximately 15×108 HeLa cells
were harvested and homogenized using a tight-ﬁtting Dounce
homogenizer. The hMTERF2-FLAG protein was puriﬁed from mito-
chondria isolated by differential centrifugation using ANTI-FLAG M2
afﬁnity gel (Sigma) according to the manufacturer's manual. Auto-
mated chemical protein sequencing (Edman degradation) was done
using a Procise 494 instrument from Applied Biosystems [19] as
described [20]. Stepwise-liberated PTH-amino acids were identiﬁed
using a ‘‘on-line’’ HPLC system [19] equipped with a PTH C18
(2.1×220 mm; 5 mm particle size) column [19].
2.3. hMTERF2-6× His protein puriﬁcation
A DNA fragment encoding the mature form of the human MTERF2
(that is, the full length protein lacking amino acids 1–35) and with a
C-terminal 6× His-tag was cloned into pET-20a(+) (Stratagene) and
expressed in E. coli strain BL21(DE3) pLysS under standard conditions.
Recombinant MTERF2 was ﬁrst puriﬁed under native conditionsthrough a manually packed column containing Ni2+-NTA matrix
superﬂow (Qiagen) and according to the manufacturer's instructions.
The peak of eluted protein was dialyzed against Buffer A [25 mM
NaH2PO4 (pH 7.0), 0.2 M NaCl, 0.5 mM EDTA (pH 8.0), 10% glycerol,
1 mM DTT, proteases inhibitors] and further puriﬁed on a 1-ml HiTrap
Heparin column (GE Healthcare) equilibrated in Buffer A. We used a
linear gradient (10 ml of Buffer A from 0.2 to 1.2 M NaCl) to elute the
protein and the fractions in which MTERF2 was eluted (between 0.4
and 0.5 M NaCl) were pooled together.
2.4. Gel ﬁltration chromatography
MTERF2 oligomerization studies were performed by gel ﬁltration
chromatography on a Superose 6 column (GE Healthcare) in Gel
Filtration Buffer [25 mM Tris–HCl (pH 7.6), 0.2 M NaCl, 3% glycerol,
1 mM DTT, and 0.5 mM EDTA]. 0.5 ml of the eluate from the heparin
puriﬁcation step (described above) was dialyzed for 4 h in Gel
Filtration Buffer and then loaded on the Superose 6 column at a ﬂow
rate of 0.4 ml/min at 4 °C. Fractions of 0.2 ml were collected, and the
protein content was analyzed by SDS-PAGE and Coomassie blue
staining. A calibration curve was prepared, following the instructions
of the column manufacturer, by running thyroglobulin (670 kDa), γ-
globulin (158 kDa), ovalbumin (44 kDa), myoglobin (17 kDa), and
vitamin B12 (1.35 kDa), all fromBioRad. The elution ofmarker proteins
was monitored by UV photometry (280 nm). The logarithm of
molecular weight was plotted against Kav, which was calculated for
each protein as follows: Kav=(Ve−Vo)/(Vt−Vo), where Ve =
elution volume for the protein, Vo= columnvoid volume (7.4ml), and
Vt = total bed volume, which is 24 ml for Superose 6.
2.5. Electrophoretic Mobility Shift Assay (EMSA)
The dsDNA binding capacity of the mature MTERF2 protein
expressed in bacteria was assayed by EMSA using dsDNA probes
covering the entire humanmtDNA. TheDNA fragmentswere ampliﬁed
by PCR using humanmtDNA as template, puriﬁed and labeled at the 5′
end by using polynucleotide kinase in the presence of [γ-32P]-ATP. A
260 bp fragment in the control region was chosen to further analyze
the non-speciﬁc DNA interaction. This fragment was ampliﬁed using
the following primers: Forward 5′-CCACCATCCTCCGTGAAATC-3′;
Reverse 5′-CAATGCTATCGCGTGCATAC-3′. Reactions were carried out
in 20 μl volumes containing 20 fmol labeled DNA template, 20 mM
Tris–HCl (pH 8.0), 0.1 mM DTT, 0.1 mg/ml BSA, 10 mM MgCl2, 5%
glycerol, and the protein concentrations indicated in the ﬁgure legend.
Poly (dI-dC)-poly (dI-dC) was used as dsDNA competitor at a ﬁnal
concentration of 0.1 μg/μl. Reactions were incubated at room
temperature for 15 min before separation in non-denaturing poly-
acrylamide TBE gels of different percentages (6–10%) according to the
DNA probe size. The gels were dried used to expose a Phosphorimager
screen, which was scanned with a Personal Molecular Imager FX (Bio-
Rad). Quantiﬁcation was carried out with Quantity One 4.6 software
(Bio-Rad). The apparent Kd was calculated as described [21]. Identical
conditionswere employed to study theMTERF1–MTERF2 interactions,
but in this case the probe was obtained by annealing the following
oligos labeled at their 5′ ends: L-strand 5′-AGA ACA GGG TTT GTT AAG
ATGGCAGAGCCCG-3′; H-strand 5′-GGATTACCGGGCTC TGCCATCTT
AAC AAA CC-3′.
2.6. Preparation of cross-linked nucleoids from mouse liver mitochondria
Mitochondria were puriﬁed from two adult mouse livers (∼3 g of
tissue) by differential centrifugation. The crudemitochondrial fraction
was resuspended in 20 ml MSH Buffer [210 mM Mannitol, 70 mM
Sucrose, 20 mM Hepes (pH 8), 2 mM EDTA, proteases inhibitors] and
layered onto preformed Percoll/Nycodenz step gradients. The gradi-
ents consisted of a ﬁrst layer of 35% Nycodenz (Axis-Shield), followed
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(Sigma), all in MSH Buffer. After the gradients were centrifuged at
25,000 rpm for 25 min in a Beckman SW32 rotor, the mitochondrial
fraction was collected from the 15/35% Nycodenz interface, diluted
four times with MSH Buffer, 0.1 ml/ml BSA was added, and ﬁnally
pelleted by centrifugation at 20,000 ×g for 15 min. The crude
mitochondrial pellet was ﬁrst treated with nucleases and then highly
puriﬁed through a sucrose gradient as described in [22]. Pure
mitochondria were resuspended in 2 ml MSH Buffer and pelleted
twice (20,000 ×g for 5 min) to wash away the sucrose residues.
Following the last centrifugation, formaldehyde cross-linking and
preparation of the mtDNA nucleoids were performed as described in
[23]. Fractions of ∼1 ml were collected from the top to the bottom of
the glycerol gradient, and assayed for DNA and protein content. More
precisely, 0.3ml of each gradient fractionwasmixedwith 0.3ml of TES
Buffer [10 mM Tris–HCl (pH 8), 1 mM EDTA, 1.5% SDS] and incubated
overnight at 65 °C to reverse the formaldehyde cross-links. About
0.4 ml of each reversed cross-link fractions was assayed for mtDNA
content; DNA was puriﬁed by extraction with phenol–CHCl3, pre-
cipitated with ethanol, and linearized with Sac I restriction endonu-
clease. mtDNA was visualized by ethidium bromide staining after
separation on agarose gel. The remaining amount of the reversed
cross-link fractions was analyzed for protein content. Proteins were
precipitated with 25% trichloroacetic acid (TCA) and 0.5 mg/ml of Na-
deoxycholate (DOC) on ice for 20 min. After 20 min centrifugation at
20,000 ×g, 4 °C, the protein pellets were washed with 200 μl of ice-
cold acetone, centrifuged as above for 5 min, air-dried and redissolved
in 25 μl of 1× Laemmli Buffer. Proteins were separated in a 4–20%
gradient SDS-PAGE gel and Western blot analysis was performed as
described later.
2.7. Western blot analysis
Livers were collected from adult mice and crude mitochondria
were prepared by differential centrifugation. Mitochondrial protein
content was determined by Bradford assay. Mouse liver mitochondria
were resuspended in 2× Laemmli Buffer for 5 min at 95 °C and
separated on a 12.5% SDS-PAGE gel. Western blot analysis was
performed as described [9] to determine the protein levels of mouse
MTERF2 and TFAM. The full-length recombinant mouse MTERF2Fig. 1.MTERF2 mitochondrial localization and identiﬁcation of its mitochondrial targeting se
mitochondria. (B) HeLa cells, stably transfected with a plasmid encoding the FLAG-tagged hu
the MTERF2 protein. The MTERF protein was identiﬁed by immunoblotting using a polyclona
the human β-actin. (D) A 35 amino acid long peptide is cleaved from the full-length humanM
shown in bold.protein was expressed and puriﬁed from bacteria and used to
immunize rabbits. The antisera used in this study were taken after
the second booster injection (Agrisera AB, Sweden). The primary
antibodies were diluted 1:500 for anti-mMTERF2 and 1:1000 for anti-
mTFAM. The quantiﬁcation of mMTERF2 and mTFAM was performed
by interpolating the intensity of their bands in the Western blot in a
calibration curve made with known amounts of recombinant proteins
using the Quantity One 4.6 software (Bio-Rad).
3. Results
3.1. MTERF2 is imported into mitochondria and cleaved upon import
We ﬁrst studied the uptake of recombinant [35S]-methionine-
labeled human MTERF2 into isolated rat mitochondria (Fig. 1A).
Import of full-length MTERF2 into mitochondria generated a protein
species of lowermolecular weight, indicating that the protein contains
a mitochondrial targeting sequence that is cleaved after import. This
process was inhibited by the addition of the uncoupler carbonyl
cyanide m-chlorophenylhydrazone (CCCP), consistent with the fact
that mitochondrial protein import across the inner membrane is
dependent on the mitochondrial membrane potential. Additionally,
the processed MTERF2 protein was resistant to trypsin treatment,
while the full-length precursor form was degraded. These data show
that MTERF2 is synthesized in the cytosol and contains an N-terminal
peptide that directs the protein towards the mitochondria. The
mitochondrial targeting sequence is cleaved after import to give rise
to the mature mitochondrial form of the protein.
3.2. Identiﬁcation of the N-terminus of the mature MTERF2 protein
To identify the N-terminal sequence of the mature protein and to
investigate the existence of MTERF2 interacting proteins, we estab-
lished stable HeLa cell lines expressing FLAG-tagged human MTERF2
protein. MTERF2-Flag expression was induced by the addition of
doxycycline and the protein expression showed a linear correlation
with the amount of added inducer (Fig. 1B). FLAG-tag afﬁnity
puriﬁcation was used to isolate the protein from total HeLa cell lysate.
Two major protein species were eluted (Fig. 1C) and MALDI-TOF
analysis identiﬁed one of them as the humanMTERF2, while the otherquence. (A) Import of radiolabeled human MTERF2 protein (hMTERF2) into isolated rat
man MTERF2 protein (hMTERF2-FLAG), show doxycyclin-dependent overexpression of
l antibody. (C) Afﬁnity puriﬁcation of the hMTERF2-FLAG protein. The asterisk indicates
TERF2 protein, upon import intomitochondria. Themitochondrial targeting sequence is
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cytoskeleton, β-actin plays an active role in organelles movements
within eukaryotic cells. However, since β-actin has not been shown to
be present within mitochondria, the functional relevance of the
observed interaction is questionable and therefore it is most likely an
artifact of the puriﬁcation procedure.
We used Edman degradation to identify the N-terminus of the
mature MTERF2 protein and found that the processing site was
localized between amino acid positions 35 and 36 of human MTERF2
(Fig. 1D). The mature human MTERF2 protein is thus 350 amino acid
long after removal of the N-terminal peptide, which contains a
number of hydrophobic and positively charged residues typical for
eukaryotic mitochondrial targeting sequences [19].
3.3. MTERF2 binds mtDNA
We expressed a His-tagged version of the mature form of the
protein in E. coli to obtain recombinant protein for characterization of
the biochemical properties of MTERF2. The recombinant protein was
puriﬁed to near homogeneity, as estimated by Coomassie blue
staining (Fig. 2A). Gel ﬁltration chromatography analysis was
employed as a last step in the puriﬁcation procedure (Fig. 2B) and
was also used to study the oligomerization status of MTERF2. In the
latter case, MTERF2 was run in parallel with standard proteins of
known molecular weight (Fig. 2C). Our analysis showed that MTERF2
has an apparent molecular mass of ∼44 kDa, which closely
corresponds to the calculated theoretical molecular weight of
40.1 kDa. We thus conclude that MTERF2 most likely is a monomer
in solution.Fig. 2. Puriﬁcation of the recombinant human MTERF2 expressed in bacteria. (A) The hum
(hMTERF2-6× His), was over-expressed in E. coli and puriﬁed to homogeneity. M: molecula
crude extract after induction of hMTERF2-6× His expression; lane 2: Ni2+-afﬁnity puriﬁcation
protein was analyzed on a Superose 6 gel ﬁltration column equilibrated with 0.2 M NaCl a
Coomassie blue. M: molecular size marker; I: input. Fraction numbers are indicated below
indicated on the top. (C) Elution curves of the protein standards (red) and hMTERF2-6× HiNext, we employed Electrophoretic Mobility Shift Assays (EMSA)
to investigate the DNA-binding activity of recombinant MTERF2. The
protein displayed a strong non-sequence-speciﬁc DNA-binding activ-
ity (Fig. 3A), with an apparent Kd of about 18 nM (Fig. 3B). Competitor
dsDNA [poly (dI-dC)-poly (dI-dC)] could efﬁciently disrupt the
observed MTERF2-DNA complex. We used two different approaches
to identify mtDNA sequences, which could be speciﬁcally bound by
MTERF2. First, we performed EMSA assays using 32 DNA fragments
covering the entire human mtDNA. Second, we performed genome-
wide chromatin immunoprecipitation (ChIP) assays with 31 primers
pairs covering the entire mouse mitochondrial genome, as previously
described for MTERF3 [17]. Neither of these two approaches showed
any sequence-speciﬁc binding of MTERF2 tomtDNA (data not shown).
Since MTERF2 is structurally related to MTERF1 [16,18], we
speculated that MTERF2 could interact with and inﬂuence the DNA
binding activity of the MTERF1 protein. HumanMTERF1 binds mtDNA
as a monomer [11] and to test if MTERF2 could interact with MTERF1,
we performed EMSA on a DNA template containing the MTERF1
binding site. MTERF1 could shift the labeled probe in the presence of a
non-speciﬁc competitor, but addition of MTERF2 did not cause a
further shift of the MTERF1-DNA complex (Fig 4). We therefore
concluded that MTERF2 does not interact withMTERF1 bound to DNA.
This result was also in agreement with our observation that MTERF1
does not interact with FLAG-MTERF2 puriﬁed fromHeLa cells (Fig 1C).
3.4. MTERF2 is an mtDNA nucleoid protein
We next explored the possibility that MTERF2 could associate with
mtDNA nucleoids. To this end, mouse liver mtDNA nucleoids werean MTERF2 protein lacking amino acids 1–35 and with a 6×-His-tag at its C-terminus
r size marker (Precision Plus Protein Standard — Dual Color, Bio-Rad); lane 1: bacterial
; lane 3: heparin puriﬁcation; lane 4: gel ﬁltration puriﬁcation. (B) The hMTERF2-6× His
nd the fractions around the elution peak were visualized on SDS-PAGE, stained with
the ﬁgure, while the approximate elution fraction of some of the protein standards is
s protein (blue) after gel ﬁltration.
Fig. 3. MTERF2 binds mtDNA. (A) Electrophoretic Mobility Shift Assays (EMSA) revealed a non sequence-speciﬁc DNA-binding activity of the hMTERF2-6× His protein. The probe
used in this experiment is a 260 bp fragment of the humanmitochondrial control region (16400–91 according to GenBank J01415), but similar results were obtainedwith 32 different
probes covering the entire human mtDNA (data not shown). (B) Measurement of the apparent Kd for the interaction between MTERF2 and DNA.
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protocol, as described [23]. Mitochondrial puriﬁcationwas carried out
as described inMaterials andmethods and 1% formaldehydewas used
to cross-link proteins associated with mtDNA. After mitochondrial
lysis, the mtDNA-proteins complexes were separated from free
proteins by sedimentation through a glycerol/Nycodenz gradient.
Following sedimentation, mtDNAwas found in a peak in the centre of
the gradient (Fig. 5A) and was associated with TFAM (Fig. 5B). TFAM
molecules not cross-linked to mtDNA remained at the top of the
gradient together with the vast majority of mitochondrial proteins.Fig. 4. MTERF1–MTERF2 interaction. EMSA was employed to test MTERF1–MTERF2 interact
(lines 2 to 4). The hMTERF2-6× His does not bind the probe either alone (lines 4 to 7) or in co
labeled DNA; lanes 2–4: 0.5, 1 and 2 pmol of hMTERF1 were added to the reaction mixture; la
8–10: increasing amounts of hMTERF2-6× His (0.5, 1 and 2 pmol) were used in combination
and 2 pmol) were used in combination with constant amount of hMTERF2-6× His (0.5 pmWhen the same gradient fractions were assayed for MTERF2, a similar
pattern to the one shown for the TFAM proteinwas observed (Fig. 5B).
We conclude thatMTERF2 is found in associationwith puriﬁedmtDNA
nucleoids and co-localizes with TFAM. MTERF2 is thus a novel
component of mtDNA nucleoids.
3.5. MTERF2 is an abundant protein
In order to quantify the levels of MTERF2 in vivo, we isolated
mitochondria from mouse liver and performed quantitative Westernions. Recombinant human MTERF1 (hMTERF1) interacted with its cognate binding site
mbinationwith hMTERF1 (lines 8 to 13). Lane 1: reaction mixture containing 20 fmol of
nes 5–7: 0.5, 1 and 2 pmol of hMTERF2-6× His were used in the reaction mixture; lanes
with constant amount of hMTERF1 (0.5 pmol); increasing amounts of hMTERF1 (0.5, 1
ol).
Fig. 5. MTERF2 is an abundant mitochondrial protein localized in the mtDNA
nucleoids. (A) Glycerol gradient sedimentation of cross-linked mouse liver mitochon-
dria. Fractions were collected from the top to the bottom of the tube and the
formaldehyde cross-links were reversed by heat treatment. (A) mtDNA was linearized
with Sac I and visualized by EtBr. (B) Fractions containing mouse MTERF2 (mMTERF2)
or mouse TFAM (mTFAM) were visualized by Western blotting. (C) The endogenous
levels of mMTERF2 and mTFAM in 30 μg of mouse liver mitochondrial lysate (L) were
determined by Western blot using as standards the indicated amounts of the full-
length mouse recombinant MTERF2 (mMTERF2) and the mouse recombinant TFAM in
its mature form (mTFAM).
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protein (Fig. 5C). The level of mouse MTERF2 protein was determined
by comparison with known amounts of recombinant protein. The
levels of MTERF2 corresponded to ∼0.07–0.1 ng per μg of total
mitochondrial protein. The relative levels of mouse TFAM protein
were determined in the same way and found to be ∼1–1.5 ng per μg
of total mitochondrial proteins. We also performed additional
experiments to calculate the ratio of MTERF2 protein to mtDNA in
isolated mouse liver mitochondria. We used a combination of
Western and Southern blot analysis together with recombinant
mouse MTERF2 protein and plasmid DNA standards (data not
shown). Our data revealed a ratio of one molecule of MTERF2 per
∼265 bp of mtDNA. Using the same approach we could measure a
ratio of one molecule of mouse TFAM per ∼10–12 bp of mtDNA,
which is in very good agreement with previous estimates in mouse
heart mitochondria [9].
The relatively high abundance of MTERF2, together with the
observation that it binds mtDNA, suggested that the protein could
regulate processes such as mtDNA replication or transcription. To
address these possibilities, we analyzed the effects of MTERF2 on DNA
replication using a previously described in vitro mtDNA replication
system, where a mini-circle template and recombinant human
mitochondrial replication factors were employed [24]. Addition of
the recombinant MTERF2 protein expressed in bacteria did not affect
the mitochondrial DNA replication in vitro (data not shown).
Similarly, addition of the MTERF2 protein failed to affect in vitro
transcription from the LSP or HSP promoters using previously
described conditions [6]. MTERF2 does not directly affect mitochon-
drial replication or transcription in the tested in vitro experimental
conditions. Of course, these ﬁndings do not exclude that MTERF2 has a
role in mtDNA replication or transcription in vivo.4. Discussion
MTERF1 has the capacity to terminate transcription initiated from
HSP2 in a recombinant in vitro system, but there is as yet no in vivo
experimental support for this mechanism. The A3243G mutation is a
common cause of mitochondrial encephalopathy, lactic acidosis as
stroke-like episodes (MELAS) syndrome and has been reported to
decrease the afﬁnity of MTERF1 for its DNA-binding site signiﬁcantly.
However, patients harboring the A3243Gmutation show no change in
levels of upstream or downstreammature mtDNA transcripts [25] and
in vivo footprinting could not reveal any signiﬁcant difference in
MTERF1 occupancy between mutant and wild-type mtDNAs [26].
The exact mechanisms of HSP1 dependent transcription termina-
tion therefore remain obscure and other factors may inﬂuence HSP1-
dependent transcription termination in vivo. In addition, LSP- and
HSP2-dependent transcriptionmust also be terminated and these may
also be regulated events. Given the homology between MTERF1 and
the other members of the MTERF family, the other MTERFs are
interesting candidates for studies of transcription termination in
mammalian mitochondria. The striking sequence similarity between
MTERF1 and MTERF2 evokes the idea that the two proteins can
contribute to transcription termination at the MTERF1 binding site.
However, the experimental evidence presented here suggests that this
is not the case. TheMTERF2 protein does not interact with theMTERF1
binding site and does not inﬂuence MTERF1 dependent transcription
termination in vitro. Future mouse knockout studies should be
performed to clarify if MTERF1 and MTERF2 alone or in combination
has roles in transcription termination.
The MTERF proteins may also inﬂuence other cellular activities.
The MTERF family of proteins has recently been linked to the
regulation of mtDNA replication [15,27]. The region of the canonical
MTERF1-binding site functions as a replication pause site and the
strength of pausing is modulated by the expression level of MTERF1
[15]. It is even possible that MTERF2, similar to MTERF3, may have a
molecular role not involving termination of transcription or replica-
tion of mtDNA. MTERF3 is repressor of transcription initiation [17] and
the protein lacks a sequence-speciﬁc DNA-binding activity as assessed
by EMSA experiments. However, ChIP experiments revealed that the
MTERF3 protein interacts with the promoter region of mtDNA. The
lack of sequence-speciﬁc binding in vitro, could indicate that MTERF3
activity is regulated in some manner, e.g. via posttranslational
modiﬁcations. Alternatively, MTERF3 binding to the promoter region
may be assisted by other factors, e.g. via direct interactions with
sequence-speciﬁc DNA binding factors.
As reported here, MTERF2 has the capacity to bind to DNA non-
sequence-speciﬁcally, and it is found in formaldehyde-crosslinked
nucleoids. The apparent lack of a sequence-speciﬁc DNA binding
activity and the physical proximity to mtDNA could suggest a role for
MTERF2 in mtDNA packaging. Further work is obviously required in
order to directly address this and other hypotheses. We hope that
disruption of the MTERF2 gene in mice will shed more light on the
molecular function of this conserved protein.
Previous reports did not identify MTERF2 as a nucleoid
component [23,28,29]. As demonstrated here, MTERF2 is present
at lower abundance than TFAM, which is a hallmark protein of
mitochondrial nucleoids. The relative scarcity of the protein may
therefore have made identiﬁcation difﬁcult. In addition, different
proteins are more or less easy to detect by mass spectrometry mass
ﬁngerprinting, which may leave some important nucleoid compo-
nents unnoticed.
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